Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 1, 2015

Primary Completion Date

May 13, 2016

Study Completion Date

May 13, 2016

Conditions
ShigellosisBacillary Dysentery
Interventions
BIOLOGICAL

Shigella flexneri 2a InvaplexAR

The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.

Trial Locations (1)

20910

Walter Reed Army Institute of Research, Clinical Trials Center, Silver Spring

All Listed Sponsors
lead

U.S. Army Medical Research and Development Command

FED

NCT02445963 - Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) | Biotech Hunter | Biotech Hunter